Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Milestone Pharmaceuticals Inc (MIST)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Milestone Pharmaceuticals Inc's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.640 +0.040    +2.50%
04:00:29 - Closed. Currency in USD ( Disclaimer )
After Hours
1.612
-0.028
-1.726%
5:14:25 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 197,748
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.580 - 1.710
Milestone Pharmaceuticals Inc 1.640 +0.040 +2.50%

Milestone Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Milestone Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

39

Equity Type

ORD

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Contact Information

Address 1111 Dr. Frederik-Philips Boulevard Suite 420
Montreal, H4M 2X6
Canada
Phone 514 336 0444
Fax -

Top Executives

Name Age Since Title
Philippe Douville 61 2005 Founder, Strategic Advisor & Member of Scientific Advisory Board
Harry A. Kopelman - - Member of the Scientific Advisory Board
John DiMarco - - Member of the Scientific Advisory Board
Harry Jefferson Leighton 77 - Member of the Scientific Advisory Board
Debra K. Liebert 67 2015 Independent Non-Executive Director
Albert L. Waldo - - Member of the Scientific Advisory Board
Michael John Tomsicek 57 2019 Independent Non-Executive Director
Daniel R. Omstead 70 2017 Observer
Joseph G. Oliveto 55 2017 CEO, President & Director
Jean-Yves Le Heuzey - - Member of the Scientific Advisory Board
John Camm - - Member of the Scientific Advisory Board
Paul Dorian - - Member of the Scientific Advisory Board
Richard C. Pasternak 74 2019 Independent Non-Executive Director
Seth H. Z. Fischer 67 2023 Independent Non-Executive Director
Peter R. Kowey - - Member of the Scientific Advisory Board
Lisa M. Giles 64 2020 Independent Non-Executive Director
Robert James Wills 69 2020 Independent Chairman of the Board
Philip T. Sager 68 2020 Chief Medical Advisor & Member of the Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MIST Comments

Write your thoughts about Milestone Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email